Abbott Biotech Ventures
Margarita Chavez
Director, Venture Investments, Abbott Biotech Ventures
APIM Therapeutics AS 
APIM Therapeutics AS is a preclinical biotech company developing novel peptide anti-cancer drugs for various oncology indications.
Targeting a novel, stress-induced therapeutic intevention point, the company’s current preclinical lead, ATX-101, sensitizes cancer cells to the action of >15 different chemotherapeutic drugs across multiple indications. The company has achieved proof-of-concept in selected in vivo and ex vivo cancer models of solid tumors (e.g. bladder, prostate) and blood cancer (myeloma, leukemia) in combination with >5 clinical drugs.
APIM Therapeutics is venture capital financed. Current investors include Sarsia Seed, Birk Venture, Ro Invest and NIK. The company is seeking to raise additional funding in 2012-2013 in order to drive continuous preclinical development of ATX-101 to IND within a period of 18 months.
Dr Konstantinos Alevizopoulos
Chief Executive OfficerSR One
SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested over $680 million in the biotech space and has a current portfolio of approximately 30 private and public companies. For more information, visit www.srone.com
Deborah Harland
General Partner
uniQure 
uniQure is a world-leading gene therapy company. Our lead product, Glybera, received a positive opinion from CHMP in July 2012 and is poised to become the first gene therapy approved in the Western World, capping more than 30 years research in this area.
This positive outcome validates uniQure's AAV platform and, most importantly, the only commercially scalable manufacturing system currently available anywhere.
uniQure's plug-and-play platform offers the opportunity to develop many additional therapies on a platform that is now validated and accepted as safe by regulatory authorities.
uniQure's second programme, for Hemophilia B ($1.5bn market) is in a Phase I/II clinical study and has shown up to 30 months stable, therapeutic expression from a single treatment (NEJM Dec 2011).
Over the coming 6 months further programmes for Porphyria, Parkinson's Disease and Sanfilippo B are expected to enter Phase I/II clinical trials.
uniQure is based in Amsterdam, and backed by Forbion, Gilde, Advent, CAPE and other investors. We would be interested in meeting to discuss potential collaborations and also potential investment opportunities.
Aicha Diba
Legal Affairs, Executive AssitantPiers Morgan
XIBER Science GmbH 
Xiber is a biopharmaceutical start–up company. Xiber develops new peptide drugs to improve outcome of critical care & transplant patients. Xiber’s peptide drugs preserve organ function & prevent organ failure. Xiber will enter market by two niche indications: Acute Lung Injury & Primary Graft Dysfunction after Lung Transplantation – with a total market volume of 630 Mio. USD.
In 2015 Xiber will complete the preclinical development for both indications. A phase I clinical trial will start in the beginning of 2016.
Xiber is a spin-off of the Medical University of Vienna. The majority of the shares is owned by the founders. The University holds a non-controlling interest and rewards its shares by providing cooperation, infrastructure, facility services and management support.
To drive its developmental program till the completion of a phase I trial Xiber needs ~ 4 Mio €. This is largely covered by Austrian funds and loans. For the remaining Xiber seeks 2 Mio € equity from VC partner. Xiber has already signed a LOI with an established VC company.
